Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inmune Bio (INMB) EBITDA (2018 - 2025)

Historic EBITDA for Inmune Bio (INMB) over the last 7 years, with Q3 2025 value amounting to -$6.5 million.

  • Inmune Bio's EBITDA rose 4786.57% to -$6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$49.6 million, marking a year-over-year decrease of 1934.43%. This contributed to the annual value of -$41.9 million for FY2024, which is 3902.62% down from last year.
  • Latest data reveals that Inmune Bio reported EBITDA of -$6.5 million as of Q3 2025, which was up 4786.57% from -$24.6 million recorded in Q2 2025.
  • Over the past 5 years, Inmune Bio's EBITDA peaked at -$4.6 million during Q1 2021, and registered a low of -$24.6 million during Q2 2025.
  • Its 5-year average for EBITDA is -$9.0 million, with a median of -$8.5 million in 2023.
  • The largest annual percentage gain for Inmune Bio's EBITDA in the last 5 years was 4786.57% (2025), contrasted with its biggest fall of 15138.92% (2025).
  • Over the past 5 years, Inmune Bio's EBITDA (Quarter) stood at -$9.6 million in 2021, then skyrocketed by 43.57% to -$5.4 million in 2022, then crashed by 57.18% to -$8.5 million in 2023, then dropped by 3.36% to -$8.8 million in 2024, then rose by 26.08% to -$6.5 million in 2025.
  • Its EBITDA was -$6.5 million in Q3 2025, compared to -$24.6 million in Q2 2025 and -$9.8 million in Q1 2025.